Payment overview · 2025
General Payments
$537.71
20 reported records · 11 companies
Healthcare provider profile · identity verified
Bethany Russell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARIS, TN · NPI 1710371117
Verified facts
What the public records show
CMS Open Payments records show Bethany Russell, M.D. received $537.71 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.49 | 27.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.80 | 16.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.73 | 14.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.18 | 9.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.50 | 9.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.72 | 5.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.06 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.39 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.18 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.59 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.07 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $537.71 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $149.49 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $77.73 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $31.72 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $10.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 131 |
| Losartan Potassium | Losartan Potassium | 440 | 113 |
| Omeprazole | Omeprazole | 419 | 121 |
| Lisinopril | Lisinopril | 406 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 102 |
| Alprazolam | Alprazolam | 367 | 47 |
| Furosemide | Furosemide | 304 | 94 |
| Gabapentin | Gabapentin | 302 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 82 |
| Citalopram Hbr | Citalopram Hydrobromide | 223 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 49 |
| Montelukast Sodium | Montelukast Sodium | 174 | 43 |
| Metformin Hcl | Metformin Hcl | 170 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 59 |
| Meloxicam | Meloxicam | 152 | 44 |
| Simvastatin | Simvastatin | 151 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 47 |
| Potassium Chloride | Potassium Chloride | 143 | 47 |
| Trazodone Hcl | Trazodone Hcl | 143 | 43 |
| Prednisone | Prednisone | 141 | 72 |
| Buspirone Hcl | Buspirone Hcl | 134 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 23 |
| Metformin Hcl Er | Metformin Hcl | 131 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 35 |
| Bupropion Xl | Bupropion Hcl | 125 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 33 |
| Eliquis | Apixaban | 123 | 27 |
| Cephalexin | Cephalexin | 118 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 35 |
| Carvedilol | Carvedilol | 108 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 41 |
| Alendronate Sodium | Alendronate Sodium | 103 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 18 |
| Glimepiride | Glimepiride | 97 | 28 |
| Sertraline Hcl | Sertraline Hcl | 94 | 24 |
| Methylprednisolone | Methylprednisolone | 85 | 71 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 82 | 27 |
| Warfarin Sodium | Warfarin Sodium | 76 | 12 |
| Allopurinol | Allopurinol | 73 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 38 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 20 |
| Jardiance | Empagliflozin | 66 | 16 |
| Lorazepam | Lorazepam | 66 | suppressed |
| Temazepam | Temazepam | 64 | 11 |
| Famotidine | Famotidine | 62 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 19 |
| Estradiol | Estradiol | 58 | 15 |
| Ozempic | Semaglutide | 58 | suppressed |
| Spironolactone | Spironolactone | 58 | 16 |
| Tramadol Hcl | Tramadol Hcl | 57 | 25 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Lovastatin | Lovastatin | 54 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 48 |
| Ibuprofen | Ibuprofen | 52 | 11 |
| Ondansetron Odt | Ondansetron | 50 | 19 |
| Fenofibrate | Fenofibrate | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 49 | 14 |
| Nystatin | Nystatin | 49 | 20 |
| Methocarbamol | Methocarbamol | 48 | 11 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Atenolol | Atenolol | 46 | 12 |
| Mupirocin | Mupirocin | 44 | 35 |
| Azithromycin | Azithromycin | 43 | 39 |
| Diazepam | Diazepam | 43 | 12 |
| Promethazine Hcl | Promethazine Hcl | 41 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 13 |
| Celecoxib | Celecoxib | 37 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Glipizide | Glipizide | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Fluconazole | Fluconazole | 25 | 15 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Colchicine | Colchicine | 22 | 11 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Digoxin | Digoxin | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 14 |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sumatriptan | Sumatriptan | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $537.71 · 20 records | Lilly USA, LLC | AIRSUPRA, Auvelity, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, GARDASIL 9, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error